These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37981702)

  • 1. Hyperfractionated Accelerated Radiotherapy Versus Stereotactic Body Radiotherapy in the Treatment of Limited-Stage Small Cell Lung Cancer: A Matched-Pair Analysis.
    Yang L; Lu X; Luo J; Huang D; Dai X; Yang Y; Dai N; Xiong Y
    Am J Clin Oncol; 2024 Mar; 47(3):115-121. PubMed ID: 37981702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of chemotherapy combined hyperfractionated accelerated radiotherapy on limited small cell lung cancer].
    Hu X; Bao Y; Chen YY; Gao JM; Wang WH; Liu Y; He H; Sun ZW; Poudel S; Wang Y; Zhuang TT; Zhang L; Chen M
    Ai Zheng; 2008 Oct; 27(10):1088-93. PubMed ID: 18851790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curative effect of hyperfractionated accelerated radiotherapy combined with EP chemotherapy regimen on limited-stage small cell lung cancer.
    Tan Y; Zhu QYXWH
    J BUON; 2021; 26(3):837-843. PubMed ID: 34268943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study.
    Li C; Xiong Y; Zhou Z; Peng Y; Huang H; Xu M; Kang H; Peng B; Wang D; Yang X
    Med Oncol; 2014 Dec; 31(12):369. PubMed ID: 25416052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
    Faivre-Finn C; Snee M; Ashcroft L; Appel W; Barlesi F; Bhatnagar A; Bezjak A; Cardenal F; Fournel P; Harden S; Le Pechoux C; McMenemin R; Mohammed N; O'Brien M; Pantarotto J; Surmont V; Van Meerbeeck JP; Woll PJ; Lorigan P; Blackhall F;
    Lancet Oncol; 2017 Aug; 18(8):1116-1125. PubMed ID: 28642008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six versus four or five cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy in patients with limited-stage small-cell lung cancer: A propensity score-matched analysis of a prospective randomized trial.
    Yu TT; Hu X; Liufu WJ; Niu SQ; Lian HM; Ma HL; Wang J; Bao Y; Chen M; Peng F
    Cancer Med; 2024 Apr; 13(8):e7215. PubMed ID: 38659392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
    Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
    J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma: A Multi-Institutional Analysis From the RSSearch Patient Registry.
    Singh R; Ansinelli H; Sharma D; Jenkins J; Davis J; Vargo JA; Sharma S
    Am J Clin Oncol; 2019 Jul; 42(7):602-606. PubMed ID: 31232723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and toxicity of induction chemotherapy with concurrent stereotactic body radiotherapy and stereotactic body radiotherapy with subsequent chemotherapy in patients with clinical stage T1-3N0M0 non-small cell lung carcinoma.
    Sun Y; Duan Q; Chen X; Chen W; Jin X; Wu R
    Clin Transl Oncol; 2017 Dec; 19(12):1498-1506. PubMed ID: 28589432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
    Rwigema JM; Verma V; Lin L; Berman AT; Levin WP; Evans TL; Aggarwal C; Rengan R; Langer C; Cohen RB; Simone CB
    Cancer; 2017 Nov; 123(21):4244-4251. PubMed ID: 28678434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperfractionated accelerated radiation therapy for non-small cell lung cancer: clinical phase I/II trial.
    Fu XL; Jiang GL; Wang LJ; Qian H; Fu S; Yie M; Kong FM; Zhao S; He SQ; Liu TF
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):545-52. PubMed ID: 9336130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.
    Grønberg BH; Halvorsen TO; Fløtten Ø; Brustugun OT; Brunsvig PF; Aasebø U; Bremnes RM; Tollåli T; Hornslien K; Aksnessæther BY; Liaaen ED; Sundstrøm S;
    Acta Oncol; 2016 May; 55(5):591-7. PubMed ID: 26494411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
    Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy 
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials.
    Viani GA; Gouveia AG; Matsuura FK; Jacinto AA; Moraes FY
    Radiother Oncol; 2022 Aug; 173():41-48. PubMed ID: 35101470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations.
    Han J; Fu C; Li B
    Radiat Oncol; 2021 Mar; 16(1):47. PubMed ID: 33663551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.
    Faivre-Finn C; Falk S; Ashcroft L; Bewley M; Lorigan P; Wilson E; Groom N; Snee M; Fournel P; Cardenal F; Bezjak A; Blackhall F
    BMJ Open; 2016 Jan; 6(1):e009849. PubMed ID: 26792218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis.
    Suzuki R; Wei X; Allen PK; Welsh JW; Cox JD; Komaki R; Lin SH
    Clin Lung Cancer; 2018 Nov; 19(6):e885-e891. PubMed ID: 30197263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Watkins JM; Wahlquist AE; Shirai K; Garrett-Mayer E; Aguero EG; Fortney JA; Sherman CA; Sharma AK
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1108-13. PubMed ID: 19084345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.